Haleon stock
Price history
−5.85% over the period1 year: from 369.50 GBp (November 17, 2025) to 347.90 GBp (November 16, 2026), −5.85%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | 347.90 GBp |
| October 30, 2026 | 319.40 GBp |
| September 30, 2026 | 337.60 GBp |
| August 28, 2026 | 368.20 GBp |
| July 31, 2026 | 363.30 GBp |
| June 30, 2026 | 347.70 GBp |
| May 29, 2026 | 336.70 GBp |
| April 30, 2026 | 340.00 GBp |
| March 31, 2026 | 373.80 GBp |
| February 27, 2026 | 405.70 GBp |
| January 30, 2026 | 378.90 GBp |
| December 31, 2025 | 374.80 GBp |
| November 28, 2025 | 370.90 GBp |
| November 17, 2025 | 369.50 GBp |
At a glance
The company
Develops and sells consumer healthcare products including oral health, vitamins and supplements, respiratory, pain relief and digestive health products across multiple brands
Latest results
Quarter to June 30, 2026 · EPS £0.04 (estimate £0.05)
TickerLandia's take on Haleon
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 19 vs a median of 26 over its last 4 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 19 vs 25 (−23%) in a group of 11.
- Strong point: Earnings stability (78/100 in its group). Weak point: Financial strength (21/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−19.76% from the 52-week high
Analysts · 18 analysts
Average target377.56 GBp+8.52% vs. price
Buy 9 · Hold 8 · Sell 1 · Buy
TickerLandia Fingerprint: Haleon
Compared with similar companies: low financial strength, high earnings stability, and low growth.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow34
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 19.2 33 EV/EBITDA 13.4 38 Forward P/E 15.5 32 Price/book 1.87 27 Price/sales 2.71 41 Profitabilityaverage48
How much it earns on revenue and capital.
Metric Value Position in group ROE 10.1% 32 Operating margin 23.5% 65 Gross margin 65.6% 55 ROA 5.1% 32 Net margin 14.6% 55 Earnings stabilityhigh78
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.9% 93 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthlow27
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +0.53% 12 Revenue growth (year over year) +2.20% 24 Earnings growth (year over year) −4.50% 45 Financial strengthlow21
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.65 20 Current ratio 0.69 1 Interest coverage 7.21 27 Debt/equitycounts in reverse: lower means more financial strength 0.50 36 Dividendaverage47
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 4 years 18 Dividend yield 2.0% 63 Payout ratio 40.6% 60 Market momentumweak35
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −4.81% 35 Relative strength (6 months) −0.99% 55 1-year return −8.42% 21 Distance from 200-day average −3.76% 29 Riskaverage54
How much the price swings.
Metric Value Position in group Volatility (60 days) 40.1% 83 Beta (1 year) 0.58 35 Maximum drawdown (12 months) 22.7% 44
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Haleon is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Haleon's P/E today is 18.8, below the median of its last 4 fiscal years (26.3; between 20.3 and 28.5 from 2022 to 2025). Haleon's P/E (trailing 12 months): 19.2, −23% against the median of a group of 11 similar companies (25.0).
Compared with 11 similar companies
| Metric | Haleon | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 19.2 | Middle | |
| Forward P/E | 15.5 | Middle | |
| Operating margin | 23.5% | Middle | |
| ROE | 10.1% | Middle | |
| Debt/equity | 0.50 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Haleon. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
£5.6B
Latest quarter · Q2 2026
Net income
£762M
Latest quarter · Q2 2026
Quarterly net margin
13.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- £30.27B
- P/E
- 19.2
- EPS
- 18.00 GBp
- Volume
- 22.39M
- Daily trading
- €177.59M
- Dividend yield
- 2.10%
- Last ex-dividend on August 13, 2026
How Haleon is changing
All resultsRevenue grew 2.2% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 150% of net income
Returns
Haleon returns with dividends
£1,000 invested in Haleon 3 years ago, on November 16, 2023, would be worth £1,122 today with dividends reinvested: +12.19% in total, +3.91% per year. On price alone it would be £1,060 (+6.03%).
| Period | Haleon | FTSE 100 | £1,000 becomes |
|---|---|---|---|
| 1 month | −7.25% | +0.53% | £927 |
| 6 months | +4.51% | +6.94% | £1,045 |
| Year to date | −7.18% | +10.15% | £928 |
| 1 year | −3.94% | +13.07% | £961 |
| 3 years | +12.19% | +47.62% | £1,122 |
Over the last 6 months it has done better than 22% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment
The chart in detail
Haleon: technical analysis
Haleon shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 16.2% below its all-time closing high (415.20 GBp, May 29, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 51
- Between 30 and 70
- vs 200-session average
- −2.84%
Support and resistance
Price areas where Haleon has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance371.95 GBp+6.91%4 touches, last on August 26, 2026
- Resistance362.60 GBp+4.23%2 touches, last on April 29, 2026
- Resistance349.90 GBp+0.57%8 touches, last on September 24, 2026
- Last price347.90 GBp
- Support326.07 GBp−6.28%3 touches, last on October 2, 2026
Volatility and risk
Over the last year it has moved less than the FTSE 100.
- Beta (1 year) vs FTSE 100
- 0.57
- Volatility (60 sessions, annualised)
- 40.1%
- Largest fall in the last year
- −22.68%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Haleon and its competitors
Haleon develops, manufactures and sells consumer healthcare products across North America, Europe, the Middle East, Africa, Latin America and the Asia Pacific. Its oral health range includes toothpastes, mouthwashes and denture care under Sensodyne, Polident, Parodontax and Biotene, while Centrum and Caltrate cover vitamins, minerals and supplements. Its over-the-counter lines span cold, flu and allergy relief under Theraflu and Flonase, pain relief under Voltaren, Panadol and Advil, and digestive products under TUMS and ENO. A collaboration with Microsoft supports its digital, data and AI work.
- Headquarters
- Weybridge, United Kingdom
- Employees
- 24,535
- Founded
- 1715
- Chief executive
- Brian McNamara
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| HaleonHLN | $40.03B | 23.5% | 19.2 | +4.51% |
| Sandoz GroupSDZ | $43.66B | 9.3% | 72.3 | +30.60% |
| Galderma GroupGALD | $53.24B | 19.1% | 66.0 | +22.82% |
| MerckMRK | $71.89B | 17.0% | 33.8 | +28.50% |
| Swedish Orphan BiovitrumSOBI | $16.42B | 30.9% | 25.0 | +8.39% |
| IpsenIPN | $15.16B | 27.4% | 26.9 | +0.60% |
Same industry or related industries, similar size. Compare Haleon with its competitors · Full profile
